The 'forgotten' cross-tolerance between phenobarbital and primidone: It can prevent acute primidone-related toxicity

Andres M Kanner, J. Parra, M. Frey

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: We report on the effect that pretreating patients with phenobarbital has on averting adverse events when primidone is introduced. Methods: Thirty patients with intractable partial epilepsy were pretreated with phenobarbital before starting primidone. Therapy with primidone was started at a dosage of 500 mg/day, and the phenobarbital was stopped. The primidone dose was then increased by 125 to 250 mg every 3 weeks until adverse events or a seizure-free state was reached. All previous antiepileptic medications were tapered down to yield a primidone monotherapy regimen. Results: Twenty-six patients (87%) tolerated the introduction of primidone with minimal or no adverse events. Only one patient had to discontinue primidone during the initial 4 weeks because of severe dizziness. This was the only patient in whom primidone monotherapy could not be reached because of adverse events. Three other patients experienced dizziness severe enough to interfere with their activities. This symptom disappeared in two patients after the dose was lowered; in the other patient, primidone was stopped and phenobarbital was restarted for another 4 days. No symptoms recurred when primidone was reintroduced on the fifth day. Conclusions: Pretreatment with phenobarbital can minimize the occurrence of intolerable adverse events associated with the introduction of primidone.

Original languageEnglish (US)
Pages (from-to)1310-1314
Number of pages5
JournalEpilepsia
Volume41
Issue number10
StatePublished - 2000
Externally publishedYes

Fingerprint

Primidone
Phenobarbital
Dizziness
Partial Epilepsy
Anticonvulsants
Seizures

Keywords

  • Intractable epilepsy
  • Partial seizure disorders
  • Pharmacologic cross-tolerance
  • Phenobarbital
  • Primidone

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

The 'forgotten' cross-tolerance between phenobarbital and primidone : It can prevent acute primidone-related toxicity. / Kanner, Andres M; Parra, J.; Frey, M.

In: Epilepsia, Vol. 41, No. 10, 2000, p. 1310-1314.

Research output: Contribution to journalArticle

@article{5d1eee9110084e9f85d2e96e02eb2ca4,
title = "The 'forgotten' cross-tolerance between phenobarbital and primidone: It can prevent acute primidone-related toxicity",
abstract = "Purpose: We report on the effect that pretreating patients with phenobarbital has on averting adverse events when primidone is introduced. Methods: Thirty patients with intractable partial epilepsy were pretreated with phenobarbital before starting primidone. Therapy with primidone was started at a dosage of 500 mg/day, and the phenobarbital was stopped. The primidone dose was then increased by 125 to 250 mg every 3 weeks until adverse events or a seizure-free state was reached. All previous antiepileptic medications were tapered down to yield a primidone monotherapy regimen. Results: Twenty-six patients (87{\%}) tolerated the introduction of primidone with minimal or no adverse events. Only one patient had to discontinue primidone during the initial 4 weeks because of severe dizziness. This was the only patient in whom primidone monotherapy could not be reached because of adverse events. Three other patients experienced dizziness severe enough to interfere with their activities. This symptom disappeared in two patients after the dose was lowered; in the other patient, primidone was stopped and phenobarbital was restarted for another 4 days. No symptoms recurred when primidone was reintroduced on the fifth day. Conclusions: Pretreatment with phenobarbital can minimize the occurrence of intolerable adverse events associated with the introduction of primidone.",
keywords = "Intractable epilepsy, Partial seizure disorders, Pharmacologic cross-tolerance, Phenobarbital, Primidone",
author = "Kanner, {Andres M} and J. Parra and M. Frey",
year = "2000",
language = "English (US)",
volume = "41",
pages = "1310--1314",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - The 'forgotten' cross-tolerance between phenobarbital and primidone

T2 - It can prevent acute primidone-related toxicity

AU - Kanner, Andres M

AU - Parra, J.

AU - Frey, M.

PY - 2000

Y1 - 2000

N2 - Purpose: We report on the effect that pretreating patients with phenobarbital has on averting adverse events when primidone is introduced. Methods: Thirty patients with intractable partial epilepsy were pretreated with phenobarbital before starting primidone. Therapy with primidone was started at a dosage of 500 mg/day, and the phenobarbital was stopped. The primidone dose was then increased by 125 to 250 mg every 3 weeks until adverse events or a seizure-free state was reached. All previous antiepileptic medications were tapered down to yield a primidone monotherapy regimen. Results: Twenty-six patients (87%) tolerated the introduction of primidone with minimal or no adverse events. Only one patient had to discontinue primidone during the initial 4 weeks because of severe dizziness. This was the only patient in whom primidone monotherapy could not be reached because of adverse events. Three other patients experienced dizziness severe enough to interfere with their activities. This symptom disappeared in two patients after the dose was lowered; in the other patient, primidone was stopped and phenobarbital was restarted for another 4 days. No symptoms recurred when primidone was reintroduced on the fifth day. Conclusions: Pretreatment with phenobarbital can minimize the occurrence of intolerable adverse events associated with the introduction of primidone.

AB - Purpose: We report on the effect that pretreating patients with phenobarbital has on averting adverse events when primidone is introduced. Methods: Thirty patients with intractable partial epilepsy were pretreated with phenobarbital before starting primidone. Therapy with primidone was started at a dosage of 500 mg/day, and the phenobarbital was stopped. The primidone dose was then increased by 125 to 250 mg every 3 weeks until adverse events or a seizure-free state was reached. All previous antiepileptic medications were tapered down to yield a primidone monotherapy regimen. Results: Twenty-six patients (87%) tolerated the introduction of primidone with minimal or no adverse events. Only one patient had to discontinue primidone during the initial 4 weeks because of severe dizziness. This was the only patient in whom primidone monotherapy could not be reached because of adverse events. Three other patients experienced dizziness severe enough to interfere with their activities. This symptom disappeared in two patients after the dose was lowered; in the other patient, primidone was stopped and phenobarbital was restarted for another 4 days. No symptoms recurred when primidone was reintroduced on the fifth day. Conclusions: Pretreatment with phenobarbital can minimize the occurrence of intolerable adverse events associated with the introduction of primidone.

KW - Intractable epilepsy

KW - Partial seizure disorders

KW - Pharmacologic cross-tolerance

KW - Phenobarbital

KW - Primidone

UR - http://www.scopus.com/inward/record.url?scp=0033775228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033775228&partnerID=8YFLogxK

M3 - Article

C2 - 11051127

AN - SCOPUS:0033775228

VL - 41

SP - 1310

EP - 1314

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - 10

ER -